Practice Experience in the Treatment of Infantile Spasms at a Tertiary Care Center

Thodeson, Drew Michael; Sogawa, Yoshimi

doi:10.1016/j.pediatrneurol.2014.07.019

Cited by 3 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So we excluded three of the trials and included the latest study by Yuskaitis et al 21 with the largest number of patients. Finally, 20 studies 21,26–44 . appropriately covered the topics, met the eligibility criteria, and were included in this review.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta‐analysis

Gong

Jiao

et al. 2023

Epilepsia Open

View full text Add to dashboard Cite

This systematic review and meta‐analysis aimed to evaluate the efficacy of vigabatrin (VGB) in treating infantile epileptic spasms syndrome (IESS). Databases of PubMed, Embase, Web of Science, MEDLINE, and Cochrane Library were systematically searched. All the relevant randomized controlled trials (RCTs) and observational studies (OSs) of VGB for IESS were included and analyzed separately. The primary outcome was the cessation of epileptic spasms (ES). Five RCTs and nine OSs compared the efficacy of VGB vs hormonal monotherapy for IESS. Meta‐analysis of the five RCTs showed that hormonal monotherapy was significantly better than VGB monotherapy (OR = 0.37, 95% CI = 0.20‐0.67) for patients with new‐onset IESS. Meta‐analysis of the nine OSs agrees with the result from RCTs (OR = 0.61, 95% CI = 0.43‐0.85). VGB was more effective in patients with TSC than in those with other etiologies (five OSs, OR = 5.59, 95% CI = 2.17‐14.41). There was no significant difference in the efficiency of VGB combined with hormonal therapy vs hormonal monotherapy for IESS (two RCTs, OR = 0.75, 95% CI = 0.09‐6.45). Hormonal monotherapy is better than VGB monotherapy for non‐TSC‐associated IESS. But for patients with IESS due to TSC, VGB is the first choice. VGB combined with hormone therapy does not definitely increase ES control rates compared with that of hormonal monotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The details of the 20 included articles are listed in Tables 1 and 2. Six RCTs and 14 OSs, including 2225 patients (1261 males, 56.7%), were published between 1996 and 2022 21,26–44 . Fourteen trials (five RCTs and nine OSs) 21,26–30,32–37,40,43 compared the efficacy of VGB vs hormonal monotherapy for IESS.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta‐analysis

Gong

Jiao

et al. 2023

Epilepsia Open

View full text Add to dashboard Cite

show abstract

“…VGB has proven to be highly effective in the treatment of IS especially in patients with TSC [13,14]. Data considering the effectiveness of VGB in focal seizures among paediatric patients is limited [15][16][17].…”

Section: Therapeutic Effectiveness Of Vgbmentioning

confidence: 99%

Vigabatrin — new data on indications and safety in paediatric epilepsy

Golec

Sołowiej

Strzelecka

et al. 2021

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients. However, reports of adverse events of VGB, including VGB-associated visual field loss and brain abnormalities in neuroimaging, have raised concerns about the broader use of VGB and thus significantly limited its application.The goal of this review was to summarise the recent therapeutic guidelines, the use of VGB in focal seizures and new VGB applications as a disease-modifying treatment in TSC patients. Moreover, we discuss the current opinions on potential VGB-associated toxicity and the safety of VGB.

show abstract

“…Vigabatrin has proven to be an effective monotherapy for infantile spasms in pediatric patients and as an add‐on therapy in adult patients with complex partial seizures . Several studies have reported efficacy of vigabatrin in partial seizures with and without tuberous sclerosis complex (TSC) etiology in the pediatric population.…”

mentioning

confidence: 99%

“…Several studies have reported efficacy of vigabatrin in partial seizures with and without tuberous sclerosis complex (TSC) etiology in the pediatric population. There is controversy with regard to efficacy of vigabatrin compared to adrenocorticotropic hormone (ACTH) and oral corticosteroids in infantile spasms in terms of seizure control and retention, as well as long‐term cognitive outcome . The literature reports varying responder rates for short‐term vigabatrin therapy of 3–6 months in a variety of refractory epilepsies, whereas the long‐term effect on seizure control and the safety profile in patients with refractory epilepsy and multiple seizure types has yet to be determined.…”

mentioning

confidence: 99%

Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy

et al. 2017

View full text Add to dashboard Cite

show abstract

Practice Experience in the Treatment of Infantile Spasms at a Tertiary Care Center

Cited by 3 publications

References 16 publications

Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta‐analysis

Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta‐analysis

Vigabatrin — new data on indications and safety in paediatric epilepsy

Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy

Contact Info

Product

Resources

About